{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T17:11:44Z","timestamp":1782321104139,"version":"3.54.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s11686-021-00337-z","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T07:53:17Z","timestamp":1612857197000},"page":"827-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Repurposing auranofin for treatment of Experimental Cerebral Toxoplasmosis"],"prefix":"10.1007","volume":"66","author":[{"given":"Iman Fathy","family":"Abou-El-Naga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3815-0955","authenticated-orcid":false,"given":"Nermine Mogahed Fawzy Hussein","family":"Mogahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,8]]},"reference":[{"issue":"9","key":"337_CR1","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.4049\/jimmunol.159.9.4452","volume":"159","author":"DG Mordue","year":"1997","unstructured":"Mordue DG, Sibley LD (1997) Intracellular fate of vacuoles containing Toxoplasma gondii is determined at the time of formation and depends on the mechanism of entry. J Immunol 159(9):4452\u20134459","journal-title":"J Immunol"},{"issue":"12","key":"337_CR2","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.pt.2011.09.005","volume":"27","author":"F Robert-Gangneux","year":"2011","unstructured":"Robert-Gangneux F, Murat JB, Fricker-Hidalgo H, Brenier-Pinchart MP, Gangneux JP, Pelloux H (2011) The placenta: a main role in congenital toxoplasmosis? Trends Parasitol 27(12):530\u2013536. https:\/\/doi.org\/10.1016\/j.pt.2011.09.005","journal-title":"Trends Parasitol"},{"key":"337_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1128\/CMR.11.2.267","volume":"11","author":"JP Dubey","year":"1998","unstructured":"Dubey JP, Lindsay DS, Speer CA (1998) Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 11:267\u2013299","journal-title":"Clin Microbiol Rev"},{"key":"337_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00436-010-1899-6","volume":"107","author":"S Skariah","year":"2010","unstructured":"Skariah S, McIntyre MK, Mordue DG (2010) Toxoplasma gondii: determinants of tachyzoite to bradyzoite conversion. Parasitol Res 107:253\u2013260","journal-title":"Parasitol Res"},{"key":"337_CR5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1093\/clinids\/15.2.211","volume":"15","author":"BJ Luft","year":"1992","unstructured":"Luft BJ, Remington JS (1992) Toxoplasmic encephalitis in AIDS (AIDS commentary). Clin Infect Dis 15:211\u2013222","journal-title":"Clin Infect Dis"},{"key":"337_CR6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.biopsych.2012.01.003","volume":"72","author":"BD Pearce","year":"2012","unstructured":"Pearce BD, Kruszon-Moran D, Jones JL (2012) The relationship between Toxoplasma gondii infection and mood disorders in the third national health and nutrition survey. Biol Psychiatry 72:290\u2013295","journal-title":"Biol Psychiatry"},{"key":"337_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1756-3305-6-191","volume":"6","author":"HV Fajard","year":"2013","unstructured":"Fajard HV, D\u2019\u00e1vila S, Bastos RR, Cyrino CD, De Lima Detoni M, Garcia JL, Das Neves LB, Nicolau JL, Amendoeira MR (2013) Seroprevalence and risk factors of toxoplasmosis in cattle from extensive and semi-intensive rearing systems at Zona da Mata, Minas Gerais state. Southern Brazil. Parasit Vectors 6:191. https:\/\/doi.org\/10.1186\/1756-3305-6-191","journal-title":"Southern Brazil. Parasit Vectors"},{"key":"337_CR8","doi-asserted-by":"publisher","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","volume":"10","author":"HX Wei","year":"2015","unstructured":"Wei HX, Wei SS, Lindsay DS, Peng HJ (2015) A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PLoS ONE 10:e0138204. https:\/\/doi.org\/10.1371\/journal.pone.0138204","journal-title":"PLoS ONE"},{"key":"337_CR9","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1128\/AAC.45.4.1271-1277.2001","volume":"45","author":"MG Reynolds","year":"2001","unstructured":"Reynolds MG, Oh J, Roos DS (2001) In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother 45:1271\u20131277","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"337_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1051\/parasite\/1998053223","volume":"5","author":"F Sordet","year":"1998","unstructured":"Sordet F, Aumjaud Y, Fessi H, Derouin F (1998) Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 5(3):223\u2013229","journal-title":"Parasite"},{"key":"337_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1021\/op500032w","volume":"18","author":"SY Dike","year":"2014","unstructured":"Dike SY, Singh D, Thankachen BN, Sharma B, Mathur PK, Kore S, Kumar AA (2014) Single-pot synthesis of atovaquone: an antiparasitic drug of choice. Org Process Re Dev 18:618\u2013625","journal-title":"Org Process Re Dev"},{"issue":"6","key":"337_CR12","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.parint.2017.08.007","volume":"66","author":"IF Abou-El-Naga","year":"2017","unstructured":"Abou-El-Naga IF, El Kerdany ED, Mady RF, Shalaby TI, Zaytoun EM (2017) The effect of lopinavir\/ritonavir and lopinavir\/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol Int 66(6):735\u2013747. https:\/\/doi.org\/10.1016\/j.parint.2017.08.007","journal-title":"Parasitol Int"},{"key":"337_CR13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.bcp.2008.08.021","volume":"76","author":"AG Cox","year":"2008","unstructured":"Cox AG, Brown KK, Arner ES, Hampton MB (2008) The thioredoxin reductase inhibitor auranofin triggers apoptosis through a Bax\/Bak-dependent process that involves peroxiredoxin 3 oxidation. Biochem Pharmacol 76:1097\u20131109. https:\/\/doi.org\/10.1016\/j.bcp.2008.08.021","journal-title":"Biochem Pharmacol"},{"key":"337_CR14","first-page":"173","volume":"8","author":"WA Katz","year":"1982","unstructured":"Katz WA, Alexander S, Bland JH, Blechman W, Bluhm GB, Bonebrake RA et al (1982) The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol Suppl 8:173\u2013178","journal-title":"J Rheumatol Suppl"},{"issue":"3","key":"337_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.4103\/1673-5374.153686","volume":"10","author":"JM Madeira","year":"2015","unstructured":"Madeira JM, Schindler SM, Klegeris AA (2015) New look at auranofin, dextromethorphan and rosiglitazone for reduction of glia-mediated inflammation in neurodegenerative diseases. Neural Regen Res 10(3):391\u2013393. https:\/\/doi.org\/10.4103\/1673-5374.153686","journal-title":"Neural Regen Res"},{"key":"337_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/mmy\/myz126","author":"IF Abou-El-Naga","year":"2019","unstructured":"Abou-El-Naga IF, Gaafar MR, Gomaa MM, Khedr SI, El Achy SN (2019) Encephalitozoon intestinalis: A new target for auranofin in a mice model. Med Mycol. https:\/\/doi.org\/10.1093\/mmy\/myz126 (myz126)","journal-title":"Med Mycol"},{"issue":"Supl.1","key":"337_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.7705\/biomedica.4891","volume":"40","author":"IF Abou-El-Naga","year":"2020","unstructured":"Abou-El-Naga IF, Mady RF, Mogahed NMFH (2020) In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum. Biom\u00e9dica 40(Supl.1):89\u2013101","journal-title":"Biom\u00e9dica"},{"issue":"1","key":"337_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4161\/gmic.22596","volume":"4","author":"A Debnath","year":"2013","unstructured":"Debnath A, Ndao M, Reed SL (2013) Reprofiled drug targets ancient protozoans. Gut Microbes 4(1):66\u201371","journal-title":"Gut Microbes"},{"key":"337_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/jeu.12706","author":"N Peroutka-Bigus","year":"2019","unstructured":"Peroutka-Bigus N, Bellaire BH (2019) Antiparasitic activity of auranofin against pathogenic Naegleria fowleri. J Eukaryot Microbiol. https:\/\/doi.org\/10.1111\/jeu.12706","journal-title":"J Eukaryot Microbiol"},{"issue":"5","key":"337_CR20","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1128\/AAC.01675-12","volume":"57","author":"N Tejman-Yarden","year":"2013","unstructured":"Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J et al (2013) A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother 57(5):2029\u20132035. https:\/\/doi.org\/10.1128\/AAC.01675-12","journal-title":"Antimicrob Agents Chemother"},{"key":"337_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.exppara.2015.05.012","volume":"166","author":"MT da Silva","year":"2016","unstructured":"da Silva MT, Silva-Jardim I, Portapilla GB, de Lima GM, Costa FC, Anibal FF, Thiemann OH (2016) In vivo and in vitro auranofin activity against Trypanosoma cruzi: Possible new uses for an old drug. Exp Parasitol 166:189\u2013193. https:\/\/doi.org\/10.1016\/j.exppara.2015.05.012","journal-title":"Exp Parasitol"},{"issue":"3","key":"337_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1021\/cb400800q","volume":"9","author":"ER Sharlow","year":"2014","unstructured":"Sharlow ER, Leimgruber S, MurrayS LA, Sciotti RJ, Hickman M et al (2014) Auranofin is an apoptosis-simulating agent Auranofin with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol 9(3):663\u2013672","journal-title":"ACS Chem Biol"},{"issue":"7","key":"337_CR23","doi-asserted-by":"publisher","first-page":"e2973","DOI":"10.1371\/journal.pntd.0002973","volume":"8","author":"RM Andrade","year":"2014","unstructured":"Andrade RM, Chaparro JD, Capparelli E, Reed SL (2014) Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl Trop Dis 8(7):e2973. https:\/\/doi.org\/10.1371\/journal.pntd.0002973","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"337_CR24","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1158\/1535-7163.mct-12-0968","volume":"12","author":"ZY Pessetto","year":"2013","unstructured":"Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK (2013) Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther 12(7):1299\u20131309. https:\/\/doi.org\/10.1158\/1535-7163.mct-12-0968","journal-title":"Mol Cancer Ther"},{"key":"337_CR25","doi-asserted-by":"publisher","first-page":"28977","DOI":"10.1074\/jbc.M109.020701","volume":"284","author":"F Angelucci","year":"2009","unstructured":"Angelucci F, Sayed AA, Williams DL, Boumis G, Brunori M, Dimastrogiovanni D et al (2009) Inhibition of Schistosoma mansoni thioredoxin-glutathione reductase by auranofin: structural and kinetic aspects. J Biol Chem 284:28977\u201328985. https:\/\/doi.org\/10.1074\/jbc.M109.020701","journal-title":"J Biol Chem"},{"key":"337_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jsb.2016.02.015","volume":"194","author":"D Parsonage","year":"2016","unstructured":"Parsonage D, Sheng F, Hirata K, Debnath A, Mckerrow JH, Reed SL et al (2016) X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. J Struct Biol 194:180\u2013190. https:\/\/doi.org\/10.1016\/j.jsb.2016.02.015","journal-title":"J Struct Biol"},{"issue":"1","key":"337_CR27","doi-asserted-by":"publisher","first-page":"e01947","DOI":"10.1128\/AAC.01947-16","volume":"61","author":"EV Capparelli","year":"2017","unstructured":"Capparelli EV, Bricker-Ford R, Rogers MJ, McKerrow JH, Reed SL (2017) Phase I clinical trial results of auranofin, a novel antiparasitic agent. Antimicrob Agents Chemother 61(1):e01947-e2016. https:\/\/doi.org\/10.1128\/AAC.01947-16","journal-title":"Antimicrob Agents Chemother"},{"key":"337_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biocel.2015.05.016","volume":"65","author":"T Gamberi","year":"2015","unstructured":"Gamberi T, Fiaschi T, Modesti A, Massai L, Messori L, Balzi M et al (2015) Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration. Int J Biochem Cell Biol 65:61\u201371. https:\/\/doi.org\/10.1016\/j.biocel.2015.05.016","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"337_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1550-7408.1976.tb03836.x","volume":"23","author":"JP Dubey","year":"1976","unstructured":"Dubey JP, Frenkel JK (1976) Feline toxoplasmosis from acutely infected mice and the development of Toxoplasma cysts. J Protozool 23(4):537\u2013546","journal-title":"J Protozool"},{"key":"337_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1742-2094-5-48","volume":"5","author":"G Hermes","year":"2008","unstructured":"Hermes G, Ajioka JW, Kelly KA, Mui E, Roberts F, Kasza K et al (2008) Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neural injury in brains of mice due to common, persistent, parasitic infection. J Neuroinflammation 5:48\u201385","journal-title":"J Neuroinflammation"},{"key":"337_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.micpath.2015.01.001","volume":"79","author":"NB Bottari","year":"2015","unstructured":"Bottari NB, Baldissera MD, Tonin AA, Rech VC, Nishihira VS, Thom\u00e9 GR et al (2015) Sulfamethoxazole-trimethoprim associated with resveratrol for the treatment of toxoplasmosis in mice: influence on the activity of enzymes involved in brain neurotransmission. Microb Pathog 79:17\u201323","journal-title":"Microb Pathog"},{"issue":"Pt A","key":"337_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.actatropica.2014.09.020","volume":"141","author":"LA El-Zawawy","year":"2015","unstructured":"El-Zawawy LA, El-Said D, Mossallam SF, Ramadan HS, Younis SS (2015) Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii. Acta Trop 141(Pt A):103\u2013111. https:\/\/doi.org\/10.1016\/j.actatropica.2014.09.020","journal-title":"Acta Trop"},{"issue":"2","key":"337_CR33","first-page":"805","volume":"20","author":"MH Eissa","year":"1990","unstructured":"Eissa MH, Antnious SN, Salama MM, Fikry AA, Morsy TA (1990) Histopathological studies of acute, chronic and congenital infection of toxoplasmosis in mice. J Egy Soc Parasitol 20(2):805\u2013816","journal-title":"J Egy Soc Parasitol"},{"issue":"6","key":"337_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.freeradbiomed.2006.12.021","volume":"42","author":"C Marzano","year":"2007","unstructured":"Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med 42(6):872\u2013881","journal-title":"Free Radic Biol Med"},{"key":"337_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lfs.2016.02.015","volume":"148","author":"D Sun","year":"2016","unstructured":"Sun D, Crowell SA, Harding CM, De Silva PM, Harrison A, Fernando DM et al (2016) KatG and KatE confer Acinetobacter resistance to hydrogen peroxide but sensitize bacteria to killing by phagocytic respiratory burst. Life Sci 148:31\u201340. https:\/\/doi.org\/10.1016\/j.lfs.2016.02.015","journal-title":"Life Sci"},{"key":"337_CR36","volume-title":"Principles and techniques of electron microscopy: biological applications","author":"MA Hayat","year":"2000","unstructured":"Hayat MA (2000) Principles and techniques of electron microscopy: biological applications. VNR Company, New York, USA"},{"key":"337_CR37","unstructured":"Kirkpatrick LA, Feeney BC (2013) A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif. Wadsworth, Cengage Learning 115"},{"issue":"10","key":"337_CR38","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1586\/erv.10.113","volume":"9","author":"EA Innes","year":"2010","unstructured":"Innes EA (2010) Vaccination against Toxoplasma gondii: an increasing priority for collaborative research? Expert Rev Vaccines 9(10):1117\u20131119. https:\/\/doi.org\/10.1586\/erv.10.113","journal-title":"Expert Rev Vaccines"},{"key":"337_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.exppara.2011.10.004","volume":"130","author":"WK Chew","year":"2012","unstructured":"Chew WK, Wah MJ, Ambu S, Segarra I (2012) Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts. Exp Parasitol 130:22\u201325","journal-title":"Exp Parasitol"},{"issue":"6","key":"337_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkf251","volume":"50","author":"O Djurkovi\u0107-Djakovi\u0107","year":"2002","unstructured":"Djurkovi\u0107-Djakovi\u0107 O, Milenkovi\u0107 V, Nikoli\u0107Bobi\u0107 AB, Gruji\u0107 J (2002) Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. JAntimicrob Chemother 50(6):981\u2013987","journal-title":"JAntimicrob Chemother"},{"key":"337_CR41","first-page":"322","volume":"13","author":"DM Israelski","year":"1993","unstructured":"Israelski DM, Remington JS (1993) Toxoplasma gondii is an intracellular protozoan parasite: toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect 13:322\u2013356","journal-title":"Curr Clin Top Infect"},{"key":"337_CR42","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jac\/dkr147","volume":"66","author":"B Faucher","year":"2011","unstructured":"Faucher B, Moreau J, Zaegel O, Frank J, Piarroux P (2011) Failure of conventional treatment with pyrimethamine and sulfadiazine for secondary prophylaxis of cerebral toxoplasmosis in a patient with AIDS. J Antimicrob Chemother 66:1654\u20131656","journal-title":"J Antimicrob Chemother"},{"key":"337_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1093\/schbul\/sbm008","volume":"33","author":"VB Carruthers","year":"2007","unstructured":"Carruthers VB, Suzuki Y (2007) Effects of Toxoplasma gondii infection on the brain. Schizophr Bull 33:745\u2013751","journal-title":"Schizophr Bull"},{"issue":"2","key":"337_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1128\/AAC.36.2.326","volume":"36","author":"H-M AraujoFG","year":"1992","unstructured":"AraujoFG H-M, Gutteridge WE, Remington JS (1992) In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother 36(2):326\u2013330","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"337_CR45","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.placenta.2009.08.002","volume":"30","author":"IN Costa","year":"2009","unstructured":"Costa IN, Angeloni MB, Santana LA, Barbosa BF, Silva MC, Rodrigues AA et al (2009) Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 30(10):884\u2013890. https:\/\/doi.org\/10.1016\/j.placenta.2009.08.002","journal-title":"Placenta"},{"issue":"10","key":"337_CR46","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1096\/fj.201700008R","volume":"31","author":"J Xue","year":"2017","unstructured":"Xue J, Jiang W, Chen Y, Gong F, Wang M, Zeng P et al (2017) Thioredoxin reductase from Toxoplasma gondii: an essential virulence effector with antioxidant function. FASEB J 31(10):4447\u20134457. https:\/\/doi.org\/10.1096\/fj.201700008R","journal-title":"FASEB J"},{"key":"337_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.pbiomolbio.2005.06.012","volume":"91","author":"AP Carvalho","year":"2006","unstructured":"Carvalho AP, Fernandes PA, Ramos MJ (2006) Similarities and differences in the thioredoxin superfamily. Prog Biophys Mol Biol 91:229\u2013248","journal-title":"Prog Biophys Mol Biol"},{"key":"337_CR48","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1093\/emboj\/17.19.5543","volume":"17","author":"EJ Stewart","year":"1998","unstructured":"Stewart EJ, Aslund F, Beckwith J (1998) Disulfide bond formation in the Escherichia coli cytoplasm: an in vivo role reversal for the thioredoxins. EMBO J 17:5543\u20135550. https:\/\/doi.org\/10.1093\/emboj\/17.19.5543","journal-title":"EMBO J"},{"key":"337_CR49","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.1073\/pnas.1504022112","volume":"112","author":"MB Harbut","year":"2015","unstructured":"Harbut MB, Vilch\u00e8ze C, Luo X, Hensler ME, Guo H, Yang B et al (2015) Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci USA 112:4453\u20134458. https:\/\/doi.org\/10.1073\/pnas.1504022112","journal-title":"Proc Natl Acad Sci USA"},{"key":"337_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10787-012-0149-1","volume":"20","author":"JM Madeira","year":"2012","unstructured":"Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20:297\u2013306. https:\/\/doi.org\/10.1007\/s10787-012-0149-1","journal-title":"Inflammopharmacology"},{"key":"337_CR51","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.lfs.2013.04.005","volume":"92","author":"JM Madeira","year":"2013","unstructured":"Madeira JM, Renschler CJ, Mueller B, Hashioka S, Gibson DL, Klegeris A (2013) Novel protective properties of auranofn: inhibition of human astrocyte cytotoxic secretions and direct neuroprotection. Life Sci 92:1072\u20131080. https:\/\/doi.org\/10.1016\/j.lfs.2013.04.005","journal-title":"Life Sci"},{"key":"337_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2014.08.615","volume":"276","author":"JM Madeira","year":"2014","unstructured":"Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A (2014) Gold drug auranofn could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst. J Neuroimmunol 276:71\u201379","journal-title":"J Neuroimmunol"},{"issue":"3","key":"337_CR53","first-page":"683","volume":"25","author":"NA Hammouda","year":"1995","unstructured":"Hammouda NA, Rashwan EA, Hussien ED, Abo el-Naga I, Fathy FM (1995) Measurement of respiratory burst of TNF and IL-1 cytokine activated murine peritoneal macrophages challenged with Toxoplasma gondii. J Egypt Soc Parasitol 25(3):683\u2013691","journal-title":"J Egypt Soc Parasitol"},{"key":"337_CR54","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s00436-012-3015-6","volume":"111","author":"AB Engin","year":"2012","unstructured":"Engin AB, Dogruman-Al F, Ercin U, Celebi B, Babur C, Bukan N (2012) Oxidative stress and tryptophan degradation pattern of acute Toxoplasma gondii infection in mice. Parasitol Res 111:1725\u20131730","journal-title":"Parasitol Res"},{"issue":"4","key":"337_CR55","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.micinf.2007.12.010","volume":"10","author":"A Gais","year":"2008","unstructured":"Gais A, Beinert N, Gross U, L\u00fcder CG (2008) Transient inhibition of poly (ADP-ribose) polymerase expression and activity by Toxoplasma gondii is dispensable for parasite-mediated blockade of host cell apoptosis and intracellular parasite replication. Microbes Infect 10(4):358\u2013366. https:\/\/doi.org\/10.1016\/j.micinf.2007.12.010","journal-title":"Microbes Infect"},{"issue":"9","key":"337_CR56","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1128\/EC.00081-08","volume":"7","author":"AE De Rocher","year":"2008","unstructured":"De Rocher AE, Coppens I, Karnataki A, Gilbert LA, Rome ME, Feagin JE et al (2008) A thioredoxin family protein of the apicoplast periphery identifies abundant candidate transport vesicles in Toxoplasma gondii. Eukaryot Cell 7(9):1518\u20131529. https:\/\/doi.org\/10.1128\/EC.00081-08","journal-title":"Eukaryot Cell"},{"key":"337_CR57","doi-asserted-by":"publisher","first-page":"D553","DOI":"10.1093\/nar\/gkm981","volume":"36","author":"B Gajria","year":"2008","unstructured":"Gajria B, Bahl A, Brestelli J, Dommer J, Fischer S, Gao X et al (2008) ToxoDB: an integrated Toxoplasma gondii database resource. Nucleic Acids Res 36:D553-556","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"337_CR58","doi-asserted-by":"publisher","first-page":"7374","DOI":"10.1128\/AAC.00057-15","volume":"59","author":"JA Portes","year":"2015","unstructured":"Portes JA, Souza TG, dos Santos TA, da Silva LL, RibeiroTP PMD et al (2015) Reduction of toxoplasma gondii development due to inhibition of parasite antioxidant enzymes by a dinuclear iron(III) compound. Antimicrob Agents Chemother 59(12):7374\u20137386. https:\/\/doi.org\/10.1128\/AAC.00057-15","journal-title":"Antimicrob Agents Chemother"},{"key":"337_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exppara.2016.02.005","volume":"164","author":"D Moncada","year":"2016","unstructured":"Moncada D, Arenas A, Acosta A, Molina D, Hernandez A, Cardona N et al (2016) Role of the 52 KDa thioredoxin protein disulfide isomerase of Toxoplasma gondii during infection to human cells. Exp Parasitol 164:36\u201342","journal-title":"Exp Parasitol"},{"key":"337_CR60","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjp.0704823","volume":"136","author":"MP Rigobello","year":"2002","unstructured":"Rigobello MP, Scutari G, Boscolo R, Bindoli A (2002) Induction of mitochondrial permeability transition by auranofin, a gold (I)-phosphine derivative. Br J Pharmacol 136:1162\u20131168","journal-title":"Br J Pharmacol"},{"issue":"2\u20133","key":"337_CR61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00726-011-0997-9","volume":"42","author":"A Ilari","year":"2012","unstructured":"Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, Gramiccia M et al (2012) A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantumin complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids 42(2\u20133):803\u2013811","journal-title":"Amino Acids"},{"issue":"20","key":"337_CR62","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1016\/j.bmcl.2004.07.073","volume":"14","author":"A Chircorian","year":"2004","unstructured":"Chircorian A, Barrios AM (2004) Inhibition of lysosomal cysteine proteases by chrysotherapeutic compounds: a possible mechanism for the antiarthritic activity of Au (I). Bioorg Med Chem Lett 14(20):5113\u20135116","journal-title":"Bioorg Med Chem Lett"},{"issue":"15","key":"337_CR63","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1021\/jm800101w","volume":"51","author":"D Krishnamurthy","year":"2008","unstructured":"Krishnamurthy D, Karver MR, Fiorillo E, Orr\u00fa V, Stanford SM, Bottini N, Barrios AM (2008) Gold(I)-mediated inhibition of protein tyrosine phosphatases: a detailed in vitro and cellular study. J Med Chem 51(15):4790\u20134795. https:\/\/doi.org\/10.1021\/jm800101w","journal-title":"J Med Chem"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-021-00337-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-021-00337-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-021-00337-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T20:10:25Z","timestamp":1697832625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-021-00337-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,8]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["337"],"URL":"https:\/\/doi.org\/10.1007\/s11686-021-00337-z","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,8]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}